Cannabis Reduction and Functional Outcomes
ConditionCannabis Use Disorder
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorMedical University of South Carolina
About this trial
This study evaluates the effects of cannabis use reduction among adults diagnosed with cannabis use disorder (CUD). Participants will undergo an 8-week intervention combining motivational interviewing, computerized cognitive behavioral therapy (CBT4CBT), and financial incentives for reduction in urinary cannabinoids. The study aims to assess improvements in cannabis-related problems, sleep, cognitive performance, CUD severity, and quality of life.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age 18+
Urinary cannabinoid level ≥ 50 ng/mL
DSM-5 diagnosis of CUD (mild, moderate, or severe)
Willingness to attempt cannabis reduction
Disqualifiers
Serious medical/psychiatric conditions
Pregnancy or breastfeeding
Use of cannabis in past 30 days was for medical purposes only
Discontinuation or reduction of cannabis use may exacerbate a pre-existing condition
Trial design
Design model
Single group
Treatments tested in this trial
CBT4CBT (Computerized Cognitive Behavioral Therapy)
BehavioralParticipants will receive one therapist-led motivational interviewing/goal setting session followed by 7 sessions of computerized CBT4CBT.
Motivational Interviewing
BehavioralParticipants will receive one therapist-led motivational interviewing/goal setting session followed by 7 sessions of computerized CBT4CBT.
Contingency Management
BehavioralPatients will receive contingent reinforcers (financial incentives for reduction in urinary cannabinoids).
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Cannabis-Related Problems
Rutgers Marijuana Problem Index (RMPI)- higher scores associated with worse outcomes.
Time frame
Week 8 (end-of-treatment)Secondary outcomes
1
Total minutes of sleep per night
Measured via Fitbit Charge.
Time frame
Week 8 (end-of-treatment)2
Minutes of light sleep per night
Measured via Fitbit Charge.
Time frame
Week 8 (end-of-treatment)3
Minutes of rapid eye movement (REM) sleep per night
Measured via Fitbit Charge.
Time frame
Week 8 (end-of-treatment)4
Minutes of deep sleep per night
Measured via Fitbit Charge.
Time frame
Week 8 (end-of-treatment)Other outcomes
1
DSM-5 CUD Criteria and Severity
Clinician-administered semi-structured interview for assessing past month DSM-5 CUD symptoms
Time frame
Week 8 (end-of-treatment)2
Quality of Life Enjoyment and Satisfaction-Q-SF
Self-report measure- range is 0-100% and higher percentages are associated with better outcomes
Time frame
Week 8 (end-of-treatment)Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Medical University of South Carolina
Lead sponsor
National Institutes of Health (NIH)
Collaborator
National Institute on Drug Abuse (NIDA)
Collaborator
Source ClinicalTrials.gov